|
2024
|
P/S
|
Pharmaceutical research and development services; conducting clinical trials for pharmaceutical p... |
|
|
P/S
|
Administering a patient support program to coordinate access to medicines; administering a patien... |
|
|
P/S
|
Providing medical information; providing medical information to patients, medical professionals, ... |
|
|
P/S
|
Providing medical information; providing medical information
to patients, medical professionals,... |
|
|
P/S
|
Pharmaceutical preparations for human use; pharmaceutical
preparations for the diagnosis, preven... |
|
|
P/S
|
Pharmaceutical preparations for human use; pharmaceutical preparations for the prevention and tre... |
|
|
P/S
|
Pharmaceutical preparations for human use; pharmaceutical preparations for the diagnosis, prevent... |
|
|
P/S
|
pharmaceutical preparations for human use; pharmaceutical preparations for the prevention and tre... |
|
|
P/S
|
Promoting the interests of people who have congenital adrenal hyperplasia and their families and ... |
|
|
Invention
|
Dosage regime of crinecerfont for treating congenital adrenal hyperplasia in a pediatric subject.... |
|
|
Invention
|
Dosage regime of crinecerfont for treating congenital adrenal hyperplasia. NSNN-prop-2-ynyl-1,3-t... |
|
|
P/S
|
Pharmaceutical research and development services; conducting clinical trials for others for pharm... |
|
|
P/S
|
Pharmaceutical preparations for human use; pharmaceutical
preparations for the prevention and tr... |
|
|
Invention
|
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-... |
|
|
P/S
|
Promoting awareness of tardive dyskinesia; Promoting the interests of people who have tardive dys... |
|
|
P/S
|
Promoting awareness of Huntington's disease and chorea associated with Huntington's disease; Prom... |
|
|
P/S
|
Promoting awareness of congenital adrenal hyperplasia and providing a public platform to discuss ... |
|
|
P/S
|
pharmaceutical preparations for human use; pharmaceutical preparations for the diagnosis, prevent... |
|
|
P/S
|
Providing medical research information; providing medical research information in the field of ph... |
|
|
P/S
|
Providing medical research information in the field of pharmaceuticals and clinical trials focusi... |
|
|
Invention
|
Deuterated compounds. The present disclosure provides deuterated compounds and their use as agoni... |
|
|
P/S
|
Pharmaceutical preparations for the diagnosis, prevention and treatment of hormonal, genetic and ... |
|
2023
|
Invention
|
Compounds and compositions as gpr52 modulators. The present disclosure relates to compounds of Fo... |
|
|
Invention
|
Compounds and compositions as gpr52 modulators. The present disclosure relates to compounds of fo... |
|
|
Invention
|
Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use. This disclosure relat... |
|
|
Invention
|
Treatment of congenital adrenal hyperplasia.
CRF1 receptor antagonists have the potential to dir... |
|
|
Invention
|
Substituted pyrido[2,1-a]isoquinolines as vmat2 inhibitors.
This disclosure relates generally to... |
|
|
Invention
|
Deuterated compounds. The present disclosure provides deuterated compounds and their use as T-typ... |
|
|
Invention
|
Deuterated compounds. The present disclosure provides deuterated compounds and their use as sodiu... |
|
|
Invention
|
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the trea... |
|
|
Invention
|
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndro... |
|
|
Invention
|
Substituted pyrido[2,1-a]isoquinolines as vmat2 inhibitors. This disclosure relates generally to ... |
|
2022
|
Invention
|
Valbenazine compositions. RRRHaa]quinolizin-2-yl ester (valbenazine) or a pharmaceutically accept... |
|
|
Invention
|
Methods of screening for vmat2 inhibitors. The present application is related to methods of prepa... |
|
|
Invention
|
Muscarinic receptor 4 antagonists and methods of use. The present invention relates to compounds ... |
|
|
Invention
|
Valbenazine for use in the add-on treatment of schizophrenia.
Provided herein are methods for th... |
|
|
Invention
|
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy.
Provided is a method o... |
|
|
Invention
|
Valbenazine for use in the add-on treatment of schizophrenia. Provided herein are methods for the... |
|
|
Invention
|
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy. Provided is a method of... |
|
|
Invention
|
Processes for preparing a vmat2 inhibitor. RSHHHHHHHH-piperazino[2,1-a]isoquinoline, and salts th... |
|
|
Invention
|
Processes for the synthesis of valbenazine.
The present application relates to processes for pre... |
|
|
Invention
|
Gpr52 modulators and methods of use.
The present disclosure relates to compounds of Formula (I) ... |
|
|
Invention
|
Gpr52 modulators and methods of use. The present disclosure relates to compounds of Formula (I) t... |
|
|
Invention
|
Processes for the synthesis of valbenazine. The present application relates to processes for prep... |
|
|
Invention
|
Processes for the synthesis of valbenazine. SR,RRR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexah... |
|
|
Invention
|
Methods for the combined administration of deutetrabenazine and a cyp2d6 inhibitor.
Provided is ... |
|
|
Invention
|
Methods for the administration of certain vmat2 inhibitors.
Provided is a method of treating a n... |
|
|
Invention
|
Methods for the administration of certain vmat2 inhibitors. Provided is a method of treating a ne... |
|
|
Invention
|
Methods for the combined administration of deutetrabenazine and a cyp2d6 inhibitor. Provided is a... |
|
|
Invention
|
Vmat2 inhibitors and methods of use. This disclosure relates generally to VMAT2 inhibitor compoun... |
|
|
Invention
|
Use of luvadaxistat for the treatment of cognitive impairment. Methods of treating at least one c... |
|
|
Invention
|
Use of luvadaxistat for the treatment of cognitive impairment. e.g.e.g., at least one cognitive s... |
|
2021
|
Invention
|
Crf receptor antagonists and methods of use.
Provided are methods related to treating congenital... |
|
|
Invention
|
Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia.
Provided are metho... |
|
|
Invention
|
Muscarinic receptor 4 antagonists and methods of use.
The present invention relates to compounds... |
|
2020
|
Invention
|
Muscarinic receptor 4 antagonists and methods of use.
Provided herein are compounds of the follo... |
|
|
Invention
|
Crf receptor antagonists and methods of use.
Compounds are provided herein that antagonize corti... |
|
|
Invention
|
Crf receptor antagonists and methods of use.
Compounds are provided herein, as well as related p... |
|
|
Invention
|
Processes for the synthesis of valbenazine.
The present application relates to processes for mak... |
